Icad Inc Cmn Stk (ICAD) 5.93 $ICAD
iCAD to Participate in the 36th Annual Canaccord Genuity Growth Conference
GlobeNewswire - Fri Jul 29, 8:00AM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present in the 36th Annual Canaccord Genuity Growth Conference in Boston, MA.
ICAD: 5.93 (+0.11)
iCAD Reports Second Quarter 2016 Financial Results
GlobeNewswire - Wed Jul 27, 3:05PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and six months ended June 30, 2016.
ICAD: 5.93 (+0.11)
iCAD To Present At The LD Micro Invitational
ACCESSWIRE - Fri Jun 03, 8:00AM CDT
NASHUA, NH / ACCESSWIRE / June 3, 2016 / iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the 6th Annual LD Micro Invitational in Los Angeles, CA.
ICAD: 5.93 (+0.11)
iCAD to Participate in the 13th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Wed May 25, 8:00AM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will participate in the 13 Annual Craig-Hallum Institutional Investor Conference in Minneapolis, MN. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
ICAD: 5.93 (+0.11)
iCAD Announces Increased Adoption Of iReveal® Automated Breast Density Solution In U.S.
PR Newswire - Mon May 23, 7:00AM CDT
iCAD (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced positive momentum in U.S. sales of its iReveal® automated breast density system, as adoption expands into several new markets.
ICAD: 5.93 (+0.11)
iCAD Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 3:01PM CDT
Reports Progress with Reimbursement Under New CPT 3 Code for the Treatment of Non-melanoma Skin Cancer with Electronic Brachytherapy
ICAD: 5.93 (+0.11)
iCAD to Host First Quarter 2016 Financial Results Conference Call on Tuesday, May 3, 2016
GlobeNewswire - Thu Apr 21, 3:00PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the first quarter ended March 31, 2016 after the market closes on Tuesday, May 3, 2016.
ICAD: 5.93 (+0.11)
iCAD Announces Computer Aided Detection Solution for Fujifilm's Aspire Cristalle Full Field Digital Mammography
BusinessWire - Mon Apr 11, 11:47AM CDT
iCAD, Inc., (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, today announced that its mammography Computer Aided Detection (CAD) solution is now available on Fujifilm's Aspire Cristalle full field digital mammography system.
ICAD: 5.93 (+0.11)
iCAD to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call on Tuesday, March 1, 2016
GlobeNewswire - Tue Feb 02, 8:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2015 after the market closes on Tuesday, March 1, 2016.
ICAD: 5.93 (+0.11)
iCad Completes Acquisition Of VuCOMP's Cancer Detection Portfolio
PR Newswire - Wed Jan 13, 8:50AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that it has completed the acquisition of the VuCOMP cancer detection portfolio, including the M-Vu® computer aided detection (CAD) technology platform. In April 2015, iCAD acquired VuCOMP's M-Vu® Breast Density software product.
ICAD: 5.93 (+0.11)
iCAD Expands Use of the Xoft Electronic Brachytherapy System in Europe, Asia and Australia
PR Newswire - Wed Dec 16, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced positive momentum for its Xoft® Electronic Brachytherapy (eBx®) System® in international markets with the adoption of eight systems for early-stage breast cancer treatment with intraoperative radiation therapy (IORT) during the third quarter of 2015. This includes four systems in Bulgaria, two systems in Taiwan, and the first systems sold in Turkey and Australia. The Xoft System is now treating patients in seven countries around the world. Outside of the United States, 23 centers are actively treating patients with the Xoft System.
ICAD: 5.93 (+0.11)
iCAD Appoints Andrew Sassine to Board of Directors
GlobeNewswire - Wed Dec 09, 3:05PM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Andrew Sassine will be joining the iCAD Board of Directors effective immediately.
ICAD: 5.93 (+0.11)
Researchers to Present Updated Data Regarding Intraoperative Radiation Therapy with the Xoft System at San Antonio Breast Cancer Symposium
PR Newswire - Tue Dec 08, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present updated data on the use of intraoperative radiation therapy (IORT) with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer during the San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The company also announced that more than 2,000 early-stage breast cancer patients have been treated to-date with IORT with the Xoft System. The Xoft System and its suite of products will be showcased at SABCS in the Xoft booth (#345) throughout the meeting from December 9-11.
ICAD: 5.93 (+0.11)
iCAD Featuring New Technology for Automated Breast Density Assessment and Showcasing Solutions for Tomosynthesis at RSNA 2015
PR Newswire - Mon Nov 30, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD) announced today that it will feature its latest solutions for advanced image analysis and workflow tools for the early identification of cancer at the Radiological Society of North American (RSNA) 2015 Annual Meeting in Chicago from November 29 to December 4, 2015. The company will showcase recent product advances including iReveal®, an automated breast density assessment solution, PowerLook® Advanced Mammography Platform, featuring the company's flagship advanced cancer detection product, VeraLook® colon polyp detection technology, and new tomosynthesis* solutions, shown as works in progress at its booth #2529-South Hall at RSNA 2015.
ICAD: 5.93 (+0.11)
iCAD To Present At The LD Micro "Main Event" Microcap Conference
ACCESSWIRE - Mon Nov 23, 8:01AM CST
NASHUA, NH / ACCESSWIRE / November 23, 2015 / iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the 8th Annual LD Micro "Main Event" Microcap Conference in Los Angeles, CA.
ICAD: 5.93 (+0.11)
iCAD Reports Use Of Xoft® Axxent® Electronic Brachytherapy System In The Treatment Of More Than 15,000 Non-Melanoma Skin Cancer Lesions
PR Newswire - Mon Nov 23, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the company's Xoft® Axxent® Electronic Brachytherapy (eBx®) System has been used in the treatment of more than 15,000 non-melanoma skin cancer (NMSC) lesions. An analysis of the 7,000 lesions collected through the Xoft System's Axxent Hub cloud-based software shows that the average age of patients treated is 74.9 years, indicating that clinicians are treating an age-appropriate group of patients for whom this technology represents an advantageous treatment option.
ICAD: 5.93 (+0.11)
iCAD's Xoft System Selected as a Popular Science Magazine "Best of What's New" Award Winner for 2015
PR Newswire - Wed Nov 18, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT) was selected as a winner in the health category of Popular Science magazine's "Best of What's New" awards for 2015. The award, selected by the editors of Popular Science, recognizes products and technologies that represent innovations that will shape the future.
ICAD: 5.93 (+0.11)
iCAD to Present at the Drexel Hamilton Micro Cap Investor Forum
GlobeNewswire - Thu Nov 05, 8:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the Drexel Hamilton Micro Cap Investor Forum in New York City.
ICAD: 5.93 (+0.11)
iCAD Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Oct 29, 3:01PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three months and nine months ended September 30, 2015.
ICAD: 5.93 (+0.11)
BUYINS.NET: ICAD SqueezeTrigger Price is $3.41. There is $422,016 That Short Sellers Still Need To Cover.
M2 - Mon Oct 19, 12:33PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring iCAD Inc (NASDAQ:ICAD) in real time and just received an alert that ICAD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 109900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.41. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ICAD: 5.93 (+0.11)
iCAD to Participate in the 36th Annual Canaccord Genuity Growth Conference
GlobeNewswire - Fri Jul 29, 8:00AM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present in the 36th Annual Canaccord Genuity Growth Conference in Boston, MA.
ICAD: 5.93 (+0.11)
iCAD Reports Second Quarter 2016 Financial Results
GlobeNewswire - Wed Jul 27, 3:05PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and six months ended June 30, 2016.
ICAD: 5.93 (+0.11)
iCAD To Present At The LD Micro Invitational
ACCESSWIRE - Fri Jun 03, 8:00AM CDT
NASHUA, NH / ACCESSWIRE / June 3, 2016 / iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the 6th Annual LD Micro Invitational in Los Angeles, CA.
ICAD: 5.93 (+0.11)
iCAD to Participate in the 13th Annual Craig-Hallum Institutional Investor Conference
GlobeNewswire - Wed May 25, 8:00AM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will participate in the 13 Annual Craig-Hallum Institutional Investor Conference in Minneapolis, MN. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
ICAD: 5.93 (+0.11)
iCAD Announces Increased Adoption Of iReveal® Automated Breast Density Solution In U.S.
PR Newswire - Mon May 23, 7:00AM CDT
iCAD (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced positive momentum in U.S. sales of its iReveal® automated breast density system, as adoption expands into several new markets.
ICAD: 5.93 (+0.11)
iCAD Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 3:01PM CDT
Reports Progress with Reimbursement Under New CPT 3 Code for the Treatment of Non-melanoma Skin Cancer with Electronic Brachytherapy
ICAD: 5.93 (+0.11)
iCAD to Host First Quarter 2016 Financial Results Conference Call on Tuesday, May 3, 2016
GlobeNewswire - Thu Apr 21, 3:00PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the first quarter ended March 31, 2016 after the market closes on Tuesday, May 3, 2016.
ICAD: 5.93 (+0.11)
iCAD Announces Computer Aided Detection Solution for Fujifilm's Aspire Cristalle Full Field Digital Mammography
BusinessWire - Mon Apr 11, 11:47AM CDT
iCAD, Inc., (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, today announced that its mammography Computer Aided Detection (CAD) solution is now available on Fujifilm's Aspire Cristalle full field digital mammography system.
ICAD: 5.93 (+0.11)
iCAD to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call on Tuesday, March 1, 2016
GlobeNewswire - Tue Feb 02, 8:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2015 after the market closes on Tuesday, March 1, 2016.
ICAD: 5.93 (+0.11)
iCad Completes Acquisition Of VuCOMP's Cancer Detection Portfolio
PR Newswire - Wed Jan 13, 8:50AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that it has completed the acquisition of the VuCOMP cancer detection portfolio, including the M-Vu® computer aided detection (CAD) technology platform. In April 2015, iCAD acquired VuCOMP's M-Vu® Breast Density software product.
ICAD: 5.93 (+0.11)
iCAD Expands Use of the Xoft Electronic Brachytherapy System in Europe, Asia and Australia
PR Newswire - Wed Dec 16, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced positive momentum for its Xoft® Electronic Brachytherapy (eBx®) System® in international markets with the adoption of eight systems for early-stage breast cancer treatment with intraoperative radiation therapy (IORT) during the third quarter of 2015. This includes four systems in Bulgaria, two systems in Taiwan, and the first systems sold in Turkey and Australia. The Xoft System is now treating patients in seven countries around the world. Outside of the United States, 23 centers are actively treating patients with the Xoft System.
ICAD: 5.93 (+0.11)
iCAD Appoints Andrew Sassine to Board of Directors
GlobeNewswire - Wed Dec 09, 3:05PM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that Andrew Sassine will be joining the iCAD Board of Directors effective immediately.
ICAD: 5.93 (+0.11)
Researchers to Present Updated Data Regarding Intraoperative Radiation Therapy with the Xoft System at San Antonio Breast Cancer Symposium
PR Newswire - Tue Dec 08, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that researchers will present updated data on the use of intraoperative radiation therapy (IORT) with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer during the San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The company also announced that more than 2,000 early-stage breast cancer patients have been treated to-date with IORT with the Xoft System. The Xoft System and its suite of products will be showcased at SABCS in the Xoft booth (#345) throughout the meeting from December 9-11.
ICAD: 5.93 (+0.11)
iCAD Featuring New Technology for Automated Breast Density Assessment and Showcasing Solutions for Tomosynthesis at RSNA 2015
PR Newswire - Mon Nov 30, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD) announced today that it will feature its latest solutions for advanced image analysis and workflow tools for the early identification of cancer at the Radiological Society of North American (RSNA) 2015 Annual Meeting in Chicago from November 29 to December 4, 2015. The company will showcase recent product advances including iReveal®, an automated breast density assessment solution, PowerLook® Advanced Mammography Platform, featuring the company's flagship advanced cancer detection product, VeraLook® colon polyp detection technology, and new tomosynthesis* solutions, shown as works in progress at its booth #2529-South Hall at RSNA 2015.
ICAD: 5.93 (+0.11)
iCAD To Present At The LD Micro "Main Event" Microcap Conference
ACCESSWIRE - Mon Nov 23, 8:01AM CST
NASHUA, NH / ACCESSWIRE / November 23, 2015 / iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the 8th Annual LD Micro "Main Event" Microcap Conference in Los Angeles, CA.
ICAD: 5.93 (+0.11)
iCAD Reports Use Of Xoft® Axxent® Electronic Brachytherapy System In The Treatment Of More Than 15,000 Non-Melanoma Skin Cancer Lesions
PR Newswire - Mon Nov 23, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the company's Xoft® Axxent® Electronic Brachytherapy (eBx®) System has been used in the treatment of more than 15,000 non-melanoma skin cancer (NMSC) lesions. An analysis of the 7,000 lesions collected through the Xoft System's Axxent Hub cloud-based software shows that the average age of patients treated is 74.9 years, indicating that clinicians are treating an age-appropriate group of patients for whom this technology represents an advantageous treatment option.
ICAD: 5.93 (+0.11)
iCAD's Xoft System Selected as a Popular Science Magazine "Best of What's New" Award Winner for 2015
PR Newswire - Wed Nov 18, 7:00AM CST
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT) was selected as a winner in the health category of Popular Science magazine's "Best of What's New" awards for 2015. The award, selected by the editors of Popular Science, recognizes products and technologies that represent innovations that will shape the future.
ICAD: 5.93 (+0.11)
iCAD to Present at the Drexel Hamilton Micro Cap Investor Forum
GlobeNewswire - Thu Nov 05, 8:00AM CST
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at the Drexel Hamilton Micro Cap Investor Forum in New York City.
ICAD: 5.93 (+0.11)
iCAD Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Oct 29, 3:01PM CDT
iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three months and nine months ended September 30, 2015.
ICAD: 5.93 (+0.11)
BUYINS.NET: ICAD SqueezeTrigger Price is $3.41. There is $422,016 That Short Sellers Still Need To Cover.
M2 - Mon Oct 19, 12:33PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring iCAD Inc (NASDAQ:ICAD) in real time and just received an alert that ICAD is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 109900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.41. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
ICAD: 5.93 (+0.11)
